Anti-fibrinolytic

Description

1. Tranexamic acid is a synthetic derivative of the amino acid lysine, providing an antifibrinolytic effect by blocking lysine-binding sites on plasminogen molecules. This action prevents plasminogen and the heavy chain of plasmin from interacting with lysine residues on fibrin. Although plasmin can still form, it is unable to bind and degrade fibrin, thereby effectively stopping bleeding.
2. Tranexamic acid is 6 to 10 times more potent in binding to plasminogen/plasmin compared to other synthetic antifibrinolytic agents like epsilon-aminocaproic acid (EACA).
3. Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. It has a dual mechanism of action on prostaglandins: it inhibits prostaglandin synthetase, reducing prostaglandin synthesis, and it also antagonizes prostaglandin at receptor sites.
4. In primary dysmenorrhea, the pain and heavy bleeding are often due to abnormal uterine activity and ischemia induced by PGF2 α release or an increased PGF2 α ratio. Mefenamic acid helps control pain and bleeding by reducing prostaglandin formation and inhibiting its receptor binding.

Indications

• For primary dysmenorrhea.
• For pain associated with menorrhagia.